Role of RPL39 in Metaplastic Breast Cancer.

TitleRole of RPL39 in Metaplastic Breast Cancer.
Publication TypeJournal Article
Year of Publication2017
AuthorsDave B, Gonzalez DD, Bin Liu Z-, Li X, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD, Radovich M, KarinaEtrovic A, Gross SS, Elemento O, Mills GB, Gilcrease MZ, Chang JC
JournalJ Natl Cancer Inst
Date Published2017 06
KeywordsAdenosine Deaminase, Animals, Cell Line, Tumor, Cell Movement, Cell Proliferation, Down-Regulation, Enzyme Inhibitors, Female, Humans, Kaplan-Meier Estimate, Metaplasia, Mice, Mutation Rate, Neoplasm Transplantation, Nitrates, Nitric Oxide Synthase Type II, Nitrites, omega-N-Methylarginine, Ribosomal Proteins, RNA, Small Interfering, RNA-Binding Proteins, Signal Transduction, STAT3 Transcription Factor, Survival Rate, Triple Negative Breast Neoplasms, Ubiquitin C

Background: Metaplastic breast cancer is one of the most therapeutically challenging forms of breast cancer because of its highly heterogeneous and chemoresistant nature. We have previously demonstrated that ribosomal protein L39 (RPL39) and its gain-of-function mutation A14V have oncogenic activity in triple-negative breast cancer and this activity may be mediated through inducible nitric oxide synthase (iNOS). The function of RPL39 and A14V in other breast cancer subtypes is currently unknown. The objective of this study was to determine the role and mechanism of action of RPL39 in metaplastic breast cancer.

Methods: Both competitive allele-specific and droplet digital polymerase chain reaction were used to determine the RPL39 A14V mutation rate in metaplastic breast cancer patient samples. The impact of RPL39 and iNOS expression on patient overall survival was estimated using the Kaplan-Meier method. Co-immunoprecipitation and immunoblot analyses were used for mechanistic evaluation of RPL39.

Results: The RPL39 A14V mutation rate was 97.5% (39/40 tumor samples). High RPL39 (hazard ratio = 0.71, 95% confidence interval = 0.55 to 0.91, P = 006) and iNOS expression (P = 003) were associated with reduced patient overall survival. iNOS inhibition with the pan-NOS inhibitor N-methyl-L-arginine acetate decreased in vitro proliferation and migration, in vivo tumor growth in both BCM-4664 and BCM-3807 patient-derived xenograft models (P = 04 and P = 02, respectively), and in vitro and in vivo chemoresistance. Mechanistically, RPL39 mediated its cancer-promoting actions through iNOS signaling, which was driven by the RNA editing enzyme adenosine deaminase acting on RNA 1.

Conclusion: NOS inhibitors and RNA editing modulators may offer novel treatment options for metaplastic breast cancer.

Alternate JournalJ. Natl. Cancer Inst.
PubMed ID28040796
PubMed Central IDPMC6245334